Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Voriconazole + micafungin is a combination of two antifungal agents used primarily in the management of invasive fungal infections, particularly those caused by Aspergillus and Candida species. Voriconazole is a triazole antifungal that inhibits fungal cytochrome P450-dependent 14α-lanosterol demethylation, disrupting ergosterol synthesis and compromising cell membrane integrity. Micafungin is an echinocandin that inhibits (1,3)-β-D-glucan synthase, thereby blocking the synthesis of an essential component of the fungal cell wall. The combination has demonstrated synergistic or additive effects against certain filamentous fungi (notably Aspergillus fumigatus) in vitro and may be considered as salvage or add-on therapy for invasive aspergillosis or refractory cases[1][2][4]. Both drugs are administered intravenously and have distinct but complementary mechanisms targeting different aspects of fungal biology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on voriconazole + micafungin.